Perphenazine Attenuates the Pro-Inflammatory Responses in Mouse Models of Th2-Type Allergic Dermatitis.
Animals
Cytokines
/ metabolism
Dermatitis, Allergic Contact
/ drug therapy
Dopamine Antagonists
/ pharmacology
Immunoglobulin G
/ metabolism
Mast Cells
/ drug effects
Mice
Mice, Inbred C57BL
NIH 3T3 Cells
Oxazolone
/ toxicity
Perphenazine
/ pharmacology
Tetradecanoylphorbol Acetate
/ toxicity
Th2 Cells
/ drug effects
dermatitis
dopamine receptor D2
drug repurposing
perphenazine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 May 2020
03 May 2020
Historique:
received:
30
03
2020
revised:
28
04
2020
accepted:
01
05
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
26
1
2021
Statut:
epublish
Résumé
Developing dermatitis therapeutics has been faced with challenges including adverse effects of topical steroid and high cost of new developing drugs. Here, we found the expression levels of dopamine receptor D2 is higher in skin biopsies of dermatitis patients and an oxazolone-induced animal model of dermatitis. We used perphenazine, an FDA-approved dopamine receptor antagonist to determine the therapeutic effect. Two different animal models including 12-o-tetradecanoylphorbol-13-acetate (TPA) and oxazolone (OXA)-induced dermatitis were employed. TPA and OXA-mediated ear swelling was attenuated by perphenazine. Moreover, perphenazine inhibited infiltrated mast cells into lesion area. We found levels of serum IgE, histamine and cytokines are decreased in mice cotreated with perphenazine and OXA compared to OXA-treated mice. Overall, this is a first study showing that the FDA-approved, anti-psychotic drug, perphenazine, alleviates animal models of dermatitis.
Identifiants
pubmed: 32375285
pii: ijms21093241
doi: 10.3390/ijms21093241
pmc: PMC7247351
pii:
doi:
Substances chimiques
Cytokines
0
Dopamine Antagonists
0
Immunoglobulin G
0
Oxazolone
15646-46-5
Perphenazine
FTA7XXY4EZ
Tetradecanoylphorbol Acetate
NI40JAQ945
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : undefined <span style="color:gray;font-size:10px;">undefined</span>
ID : GC101
Références
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S53-S62
pubmed: 29248518
Int J Impot Res. 2000 Oct;12 Suppl 4:S26-33
pubmed: 11035383
J Neuroimmunol. 2017 Feb 15;303:99-107
pubmed: 28077213
Sci Rep. 2020 Mar 11;10(1):4493
pubmed: 32161331
Handb Exp Pharmacol. 2012;(212):53-86
pubmed: 23129328
Br J Cancer. 2017 Aug 8;117(4):513-524
pubmed: 28697173
West J Med. 1995 Feb;162(2):123-6
pubmed: 7794369
J Allergy Clin Immunol. 2016 Aug;138(2):336-49
pubmed: 27497276
Biomed Res Int. 2015;2015:496759
pubmed: 26693483
Sci Rep. 2020 Mar 17;10(1):4887
pubmed: 32184439
Int J Mol Sci. 2018 Oct 09;19(10):
pubmed: 30304837
FEBS Lett. 2012 Sep 21;586(19):3057-63
pubmed: 22819825
J Am Acad Dermatol. 2006 Jan;54(1):1-15; quiz 16-8
pubmed: 16384751
Cell Death Differ. 2011 Dec;18(12):1865-75
pubmed: 21597459
Br J Clin Pharmacol. 1986 Dec;22(6):715-7
pubmed: 3567016
J Allergy Clin Immunol. 2015 Jan;135(1):153-63
pubmed: 25567045
J Dermatol Sci. 2013 Jul;71(1):37-44
pubmed: 23639699
BMC Psychiatry. 2006 Feb 21;6:8
pubmed: 16504026
J Immunol Res. 2016;2016:3160486
pubmed: 27795960
Brain Behav Immun. 2010 May;24(4):525-8
pubmed: 19896530
Bosn J Basic Med Sci. 2013 May;13(2):119-25
pubmed: 23725509
Front Immunol. 2014 Mar 21;5:117
pubmed: 24711809
J Pharmacol Sci. 2011;116(3):274-82
pubmed: 21691039
Ther Adv Neurol Disord. 2018 May 10;11:1756286418774225
pubmed: 29774058
J Neuroimmunol. 2015 Dec 15;289:43-55
pubmed: 26616870
Br J Pharmacol Chemother. 1963 Jun;20:497-506
pubmed: 14028829
Curr Allergy Asthma Rep. 2019 Nov 27;19(12):57
pubmed: 31776678
Immunol Rev. 2011 Jul;242(1):233-46
pubmed: 21682749
Front Immunol. 2019 May 01;10:981
pubmed: 31118938
Allergy. 2006 Sep;61(9):1132-7
pubmed: 16918518
J Allergy Clin Immunol. 2017 Apr;139(4S):S65-S76
pubmed: 28390479
J Immunol. 2016 May 15;196(10):4143-9
pubmed: 27183640
Sci Immunol. 2020 Feb 14;5(44):
pubmed: 32060143
J Biol Chem. 2010 Aug 27;285(35):27026-32
pubmed: 20592018
Adv Pediatr. 2007;54:241-73
pubmed: 17918474
Arch Pharm Res. 2004 Jan;27(1):94-8
pubmed: 14969346
Stem Cells Transl Med. 2013 Dec;2(12):929-34
pubmed: 24167319
Skin Pharmacol. 1991;4(4):262-71
pubmed: 1789987
BMC Syst Biol. 2009 Feb 12;3:19
pubmed: 19216740
FEBS Lett. 2010 Apr 16;584(8):1565-70
pubmed: 20226183
J Invest Dermatol. 2009 Jan;129(1):31-40
pubmed: 19078986
Biomedicines. 2020 Jan 24;8(2):
pubmed: 31991554
Nat Immunol. 2018 Dec;19(12):1286-1298
pubmed: 30446754